By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

Unlearn.ai's method for late-phase trials (PROCOVA) is acceptable to regulators because it's designed to statistically correct for any bias in the digital twin model. This ensures the model's inaccuracy doesn't affect the trial's final decision procedure or error rate, a critical feature distinguishing it from simply replacing the control arm.

Instead of the high-risk approach of replacing a trial's control arm with digital twins, Unlearn.ai adds counterfactual data to every participant. This method increases a trial's statistical power, allowing for smaller control arms or a higher chance of success, while satisfying regulatory constraints for pivotal trials.

With digital twins for drug testing and local 3D printing of drugs, pharma's role could shift from mass manufacturing to licensing molecule formulas. A doctor would test a drug on a digital twin and a pharmacy would print the personalized dose on site.

AI's primary value in early-stage drug discovery is not eliminating experimental validation, but drastically compressing the ideation-to-testing cycle. It reduces the in-silico (computer-based) validation of ideas from a multi-month process to a matter of days, massively accelerating the pace of research.

The highest-value application of AI in clinical development is in the design phase. By simulating trial outcomes with historical data and virtual patient cohorts, companies can identify and resolve potential bottlenecks, like flawed protocols or recruitment issues, before committing massive resources. This

It's impossible to generate human data at the scale of in silico experiments. The key is to create highly accurate simulations of human physiology (digital twins) and then validate their predictions with limited, strategic human data. If the model proves reliable, it could drastically accelerate R&D.

Conquer's Farsight Twin can predict a patient's response to a novel drug, standard of care, and the combination therapy separately. This allows pharma companies to determine if a positive response in an early-phase trial is truly driven by their new asset or just the background therapy, providing crucial efficacy data.

AI models mirror a bioreactor in real time, creating a "digital twin." This allows operators to test process changes and potential failure modes virtually, without touching the actual, expensive physical system, much like having a virtual engineer working alongside them.